Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :474
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded216    
    Comments [Add]    
    Cited by others 4    

Recommend this journal


Year : 2015  |  Volume : 52  |  Issue : 3  |  Page : 297-298

Eribulin mesylate in Indian patients: A single center experience

1 Department of Medical Oncology, Sri Shankara Cancer Hospital and Research Centre, Bengaluru, Karnataka, India
2 Department of Medical Oncology, HCG Bangalore Institute of Oncology Speciality Centre, Bengaluru, Karnataka, India
3 Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India

Correspondence Address:
S Patil
Department of Medical Oncology, HCG Bangalore Institute of Oncology Speciality Centre, Bengaluru, Karnataka
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0019-509X.176735

Rights and Permissions

Background: Eribulin mesylate is the latest addition in the armamentarium of management of metastatic breast cancer (MBC) with a unique mechanism of action. Although the multicentric EMBRACE trial suggests significant overall survival benefit from this novel drug, its effectiveness in Indian population is yet to be evaluated. Materials And Methods: Presented here is a single center experience of eight patients who were administered eribulin for MBC. Patients had received a median of 3 prior chemotherapies before eribulin administration. The median dose of eribulin therapy was 5 cycles (range: 2–6 cycles). Results: The objective response rate was 75% (CR in one and PR in five out of eight patients). Response was seen across all subtypes of patients. Eribulin was well tolerated. No serious adverse events were reported. Conclusion: Eribulin conferred good response rates with satisfactory tolerability profile in Indian patients. Its use in earlier lines and in combination with other drugs may achieve deeper and longer responses.


Print this article     Email this article

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow